NCT01023282
Completed
Phase 1
Randomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary Measure
NeuroSearch A/S2 sites in 1 country22 target enrollmentNovember 2009
Overview
- Phase
- Phase 1
- Intervention
- ACR325
- Conditions
- Parkinson's Disease
- Sponsor
- NeuroSearch A/S
- Enrollment
- 22
- Locations
- 2
- Primary Endpoint
- Safety and tolerability
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of idiopathic Parkinson"s disease according to the United Kingdom Parkinson's Disease Society brain bank diagnostic criteria
- •Levodopa induced dyskinesia
Exclusion Criteria
- •Previous surgery for Parkinson's disease
- •Any current or history of heart condition or increased pro-arrhythmic risk
- •Severe or ongoing unstable medical condition
Arms & Interventions
ACR325
Intervention: ACR325
Placebo
Intervention: ACR325
Placebo
Intervention: Placebo
Outcomes
Primary Outcomes
Safety and tolerability
Time Frame: 4 weeks
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 2
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic TreatmentParkinson DiseaseNCT04369430Alkahest, Inc.110
Completed
Phase 1
Safety and Tolerability Study of K0706 in Subjects With Parkinson's DiseaseParkinson DiseaseNCT02970019Sun Pharma Advanced Research Company Limited60
Recruiting
Phase 2
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's DiseaseParkinson DiseaseNCT04691661Il-Yang Pharm. Co., Ltd.40
Completed
Phase 3
A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's DiseaseParkinson's DiseaseNCT00242008UCB Pharma
Completed
Phase 4
The Effect of Donepezil on Gait and Balance in Parkinson's DiseaseParkinson's DiseaseNCT01521117Oregon Health and Science University21